VEGF Overexpression Is a Valuable Prognostic Factor for Non-Hodgkin’s Lymphoma Evidence from a Systemic Meta-Analysis

Table 2

Stratified analysis of pooled hazard ratios of NHL patients with VEGF overexpression.

Stratified analysis	Number of studies	Number of patients	Pooled HR (95% CI)	value	Heterogeneity		Interaction value
					(%)	value
Study location							0.512
Asia	7	798	1.9 (1.21–2.97)	0.005	59.6	0.021
Europe and America	7	720	1.5 (1.03–2.18)	0.034	72.6	0.001
Number of patients							0.311
>100	6	874	1.88 (1.29–2.75)	0.001	56.3	0.043
<100	8	644	1.42 (1-2)	0.047	56.2	0.025
Source of VEGF							0.165
Serum	7	801	1.37 (0.96–1.95)	0.087	67.7	0.005
Surgical tissue	7	717	1.95 (1.41–2.69)	0	30.4	0.196
NOS score							0.288
>5	11	1343	1.75 (1.3–2.36)	0	49.3	0.032
≦5	3	175	1.27 (0.78–2.06)	0.333	55.9	0.104